These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20706125)

  • 61. [FDA approval for the antidepressive drug Cymbalta].
    Krankenpfl J; 2004; 42(5-6):154. PubMed ID: 15527218
    [No Abstract]   [Full Text] [Related]  

  • 62. Duloxetine--three birds with one stone?
    Michel MC
    Int J Clin Pract; 2007 Aug; 61(8):1247-8. PubMed ID: 17627705
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 65. Determination of Patient Adherence for Duloxetine in Urine.
    Mulder HA; McIntire GL; Wallace FN; Poklis JL
    J Anal Toxicol; 2022 Oct; 46(8):905-910. PubMed ID: 35748596
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
    Bellino S; Paradiso E; Bozzatello P; Bogetto F
    J Psychopharmacol; 2010 Mar; 24(3):333-9. PubMed ID: 18719047
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Duloxetine-induced cutaneous adverse reaction.
    Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
    J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
    [No Abstract]   [Full Text] [Related]  

  • 68. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
    Bech P; Kajdasz DK; Porsdal V
    Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study.
    Härmark L; van Puijenbroek E; van Grootheest K
    Eur J Clin Pharmacol; 2013 Feb; 69(2):209-15. PubMed ID: 22688722
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.
    Lobo ED; Quinlan T; Prakash A
    Clin Pharmacokinet; 2014 Aug; 53(8):731-40. PubMed ID: 24989060
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
    Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
    Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
    Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
    Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment with duloxetine in adults and the incidence of cardiovascular events.
    Xue F; Strombom I; Turnbull B; Zhu S; Seeger J
    J Clin Psychopharmacol; 2012 Feb; 32(1):23-30. PubMed ID: 22198454
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
    Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
    Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
    Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
    J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful treatment of refractory hypochondriasis with duloxetine.
    Politi P; Emanuele E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1145-6. PubMed ID: 17493731
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.